Meridia Needs Continued Intensive Monitoring For Pediatric Adverse Events
Executive Summary
Pediatric adverse events associated with Abbott's weight-loss agent Meridia should be monitored more intensively for a second year, FDA's Pediatric Advisory Committee unanimously recommended